Rezolute Reports Enrollment Completion in P-III (upLIFT) Trial of Ersodetug in Tumor Hyperinsulinism

Shots: Rezolute has completed enrolment in the P-III (upLIFT) trial assessing ersodetug in 16 pts with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI), with topline data expected mid-Dec 2026 Earlier this year, 7 of 8 pts enrolled in the study’s first half met the 1EP responder criterion, with…

ByRidhi Rastogi1 day ago

Medtronic Reports the European CE Mark of MiniMed 780G System for Automated Insulin Delivery

Shots: Medtronic has received CE mark to extend label of MiniMed 780G system to pts (≥2yrs.), pregnant women & T2D pts; application is under the FDA’s review for T2D, plus US trial for use in pts (2-6yrs.) is underway Approval was backed by extensive clinical data incl. LENNY trial data in T1D pts (2–6 yrs), showing a…

ByRidhi RastogiJuly 22, 2025

PharmaShots Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

In an interview with PharmaShots, Emmanuel Dulac, Pharm.D., Ph.D., President and CEO of Zealand Pharma shares insight on the US FDA's approval of Zegalogue and its availability in both an auto-injector and a prefilled syringe in June 2021. He also highlighted the importance of approval for the company and patients with hypoglycemia. Shots: The approval is based…

BySenior EditorApril 28, 2021

Rezolute Reports Enrollment Completion in P-III (upLIFT) Trial of Ersodetug in Tumor Hyperinsulinism

Medtronic Reports the European CE Mark of MiniMed 780G System for Automated Insulin Delivery

PharmaShots Interview: Zealand Pharma’s Emmanuel Dulac Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes

Contact US

FOLLOW US